Clive Svendsen, PhD
Director, Regenerative Medicine Institute
|Regenerative Medicine Institute|
|Professor, Biomedical Sciences|
Awards and Activities
|American Acadamy of Neurology||2010|
|Huntington Disease Trailblazer Award||2009|
|Statuette Award, International Academy for Child Brain Development||2006|
|Bernard Sanberg Memorial Award for Brain Repair||2005|
|Editorial Board: Experimental Neurology||Current|
Modeling and treating neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and Parkinson's disease using a combination of stem cells and powerful growth factors.
Leader in human neural stem cell biology.
Current investigations include:
Basic: Studying induced pluripotent stem (iPS) cells which replay disease processes in vitro, examining some of the mechanisms underlying this phenomenon, and starting to screen drugs that might reverse or slow down this degeneration
Translational: Have produced a clinical grade human neural progenitor (hNPC) cell bank derived from one fetal brain tissue sample which can be expanded to enormous numbers for use in thousands of patient trials.
- Ebert AD, Yu J, Rose Jr, Mattis VB, Lorson CL, Thomson JA, Svendsen CN: Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature, 457(7227): 277-80, 2008
- Suzuki M, Svendsen CN: Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis. Trends Neurosci., 31(4): 192-8, 2008
- Suzuki M, McHugh J, Tork C, Shelley B, Klein SM, Aebischer P, Svendsen CN: GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS ONE, 2(1): e689, 2007
- Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen CN, Heywood P: Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med., 9(5): 589-95, 2003